The market for Antibody-drug Conjugates (ADCs) in oncology presents significant opportunities with over 200 companies and 220 drugs in development globally. ADCs offer high specificity and reduced ...

Global Cancer Antibody Drug Conjugates Market poised to exceed USD 70 billion by 2031, driven by over 20 approved drugs. Report offers insights into market size, sales, pricing, and clinical trials ...

The cancer antibody conjugate market is rapidly expanding, highlighted by increased patent filings and clinical trials. Key opportunities include strategic positioning in antibody, linker, and payload ...

You may have heard of the consulting firm Gartner’s technology hype cycle—the technology trigger, the peak of inflated expectations, the trough of disillusionment, the slope of enlightenment, and the ...

The conjugate space is evolving fast - moving beyond traditional ADCs into new formats like degrader-conjugates, oligonucleotide conjugates, bispecific ADCs, and more. The 4 th Novel Conjugates Summit ...

Chemotherapy is one of the most widely used cancer therapies; however, chemotherapy often causes serious side effects. Antibody-drug conjugates (ADCs) are promisingly emerging cancer therapies that ...

A panelist discusses how antibody-drug conjugates like mirvetuximab should be sequenced in platinum-resistant ovarian cancer, recommending it as first-line therapy for folate receptor alpha–high ...

Please provide your email address to receive an email when new articles are posted on . Patients on ADCs with known ocular side effects require close ophthalmic monitoring. A cycle of topical ...

Although just two ADCs, Seattle Genetics’ Adcetris and Roche’s Kadcyla, are on the market, they are proof that the products are technically feasible, therapeutically effective, and able to get ...

Linking therapeutically active molecules to specific antibodies can help to pilot them to their designated targets and minimize side effects--especially when treating tumors. In the journal Angewandte ...